ILL9 Antibody

What is IL-9 and why are antibodies against it significant in immunological research?

IL-9 is a pleiotropic cytokine historically associated with type 2 immune responses but now recognized to be produced by a distinct T-helper lineage called Th9. It functions as a proinflammatory mediator with multiple effects on various cell types including Th2 lymphocytes, B lymphocytes, mast cells, eosinophils, and epithelial cells in the gut and airways . IL-9 belongs to the common cytokine receptor gamma chain-dependent family of cytokines, which also includes IL-2, IL-4, IL-7, IL-15, and IL-21 .

Antibodies against IL-9 are significant in immunological research because they allow scientists to:

• Neutralize IL-9 activity in experimental models to understand its functional roles

• Study the consequences of IL-9 blockade in allergic and inflammatory conditions

• Develop potential therapeutic strategies for conditions where IL-9 plays a pathological role

• Detect and quantify IL-9 expression in different tissues and cell populations

Recent studies have shown that anti-IL-9 antibodies can decrease allergic inflammation by suppressing Th2 and Th17 cells while enhancing regulatory T cell effects, suggesting potential therapeutic applications in allergic airway diseases .

How are IL-9 antibodies detected and quantified in experimental settings?

IL-9 antibodies can be detected and quantified using several methodological approaches:

Flow Cytometry:
IL-9 antibodies conjugated with fluorochromes (such as APC) can be used to detect intracellular IL-9 in cells. This requires cell fixation and permeabilization protocols such as those using Intracellular Fixation & Permeabilization Buffer Sets . For example, human peripheral blood mononuclear cells (PBMCs) can be treated with anti-CD3, anti-CD28, recombinant human IL-4, and anti-human IFN-gamma, and then stained with anti-human IL-9 antibodies for flow cytometric analysis .

Western Blot:
IL-9 antibodies can detect IL-9 in cell lysates. For example, using human Th2 cells treated with various stimuli, IL-9 can be detected as a band of approximately 35-40 kDa on a PVDF membrane probed with anti-IL-9 antibodies .

Immunohistochemistry:
Rabbit polyclonal IL-9 antibodies have been shown suitable for immunohistochemistry on paraffin-embedded tissue sections (IHC-P) .

ELISA:
ELISA-based screening methods can be employed to detect IL-9 antibodies, particularly when assessing their specificity and functionality .

Quantification typically involves comparison to standards of known concentration or relative quantification against control samples.

What are the key characteristics of commercially available IL-9 antibodies for research use?

Commercial IL-9 antibodies come in various formats with specific characteristics suited for different research applications:

When selecting an IL-9 antibody for research, investigators should consider:

• The specific application (flow cytometry, Western blot, IHC, neutralization)

• Species reactivity (human vs. mouse)

• Clonality (monoclonal vs. polyclonal)

• Conjugation status (unconjugated vs. fluorophore-conjugated)

• Validated experimental protocols provided by manufacturers

How do anti-IL-9 antibodies affect allergic inflammation mechanisms in experimental models?

Anti-IL-9 antibodies demonstrate multiple significant effects on allergic inflammation pathways in experimental models:

Suppression of Th2 Responses:
In allergic rhinitis mouse models, administration of anti-IL-9 antibody significantly decreases mRNA expression of IL-4 (a key Th2 cytokine) compared to control groups . This suppression of Th2 responses contributes to reduced allergic inflammation.

Inhibition of Th17 Pathways:
Anti-IL-9 antibodies reduce the expression of ROR-γt (a transcription factor for Th17 cells) at both mRNA and protein levels, as well as decreasing IL-17 mRNA levels . This inhibition of the Th17 pathway further dampens inflammatory responses.

Enhancement of Regulatory T Cell Function:
Treatment with anti-IL-9 antibody increases Foxp3 and IL-10 mRNA expression, enhances Foxp3 protein levels, and promotes the induction of CD4+CD25+Foxp3+ T cells . This enhancement of regulatory T cell function contributes to immune tolerance.

Reduction in IgE Production:
Anti-IL-9 antibody administration significantly decreases serum OVA-specific IgE levels compared to both allergic rhinitis models and oral tolerance groups without antibody treatment .

Decreased Eosinophil Infiltration:
In nasal mucosa, anti-IL-9 antibody treatment results in reduced eosinophil infiltration, a key cellular component of allergic inflammation .

Suppression of Th9-Related Transcription Factors:
The expression of PU.1 (a transcription factor for Th9 cells) is significantly lower in groups treated with anti-IL-9 antibody , suggesting direct interference with the development of IL-9-producing cells.

These findings collectively demonstrate that anti-IL-9 antibodies act through multiple immunomodulatory mechanisms to reduce allergic inflammation, affecting T cell differentiation, antibody production, and cellular infiltration processes.

What is the role of machine learning in predicting IL-9 antibody targets and functions?

Machine learning has emerged as a powerful tool for predicting antibody targets and functions, with specific applications to IL-9 antibodies:

Genetic Sequence-Based Prediction:
Recent research from the University of Illinois Urbana-Champaign demonstrated that machine learning models can predict what pathogens antibodies will target based on their genetic sequences . While this study focused on distinguishing between antibodies against influenza and SARS-CoV-2, the approach has broad implications, including for IL-9 antibodies.

Training Data Requirements:
For effective prediction, these models require substantial training data. Researchers used antibody data from 88 published studies and 13 patents to train their model . Similar approaches for IL-9 antibodies would require comprehensive datasets of IL-9-specific antibody sequences and their functional characteristics.

Potential Applications for IL-9 Antibody Research:

• Predicting which specific epitopes on IL-9 an antibody will bind to based on sequence data

• Estimating the neutralizing capacity of IL-9 antibodies without extensive laboratory testing

• Designing antibodies with enhanced specificity for IL-9 or particular functional domains

• Identifying antibodies that might cross-react with other cytokines in the same family

Future Directions:
Researchers believe that with sufficient data, they can improve these models to precisely determine which parts of targets like IL-9 the antibodies attack . This could eventually lead to the ability to design antibodies that bind to specific regions of IL-9, potentially enhancing therapeutic efficacy.

Machine learning approaches represent a significant advancement in antibody research by potentially reducing the time and resources required for experimental validation while improving antibody design and selection processes.

How does the combination of oral tolerance and anti-IL-9 antibody treatment affect immunological parameters?

The combination of oral tolerance (OT) and anti-IL-9 antibody treatment produces synergistic immunomodulatory effects that exceed those of oral tolerance alone, as demonstrated in experimental models of allergic rhinitis:

Enhanced Suppression of Allergic Symptoms:
When anti-IL-9 antibody is administered during oral tolerance induction, allergic symptoms are significantly reduced compared to oral tolerance alone. In mouse models, this combination therapy showed superior efficacy in decreasing symptom scores including sneezing and nasal rubbing .

Synergistic Effects on Serum IgE Levels:
The OT+IL9AB group displayed significantly lower serum OVA-specific IgE than the OT group alone (P=0.010), indicating that anti-IL-9 antibody enhances the ability of oral tolerance to decrease allergen-specific IgE synthesis .

Differential Effects on T Helper Cell Subsets:

• Th1 Responses: No significant difference in IFN-γ and T-bet mRNA expression was detected between OT and OT+IL9AB groups, suggesting the combination does not affect Th1 responses .

• Th2 Responses: The OT+IL9AB group showed significantly lower expression of IL-4 (a Th2 cytokine) compared to the OT group .

• Th9/Th17 Responses: The OT+IL9AB group had significantly lower PU.1 mRNA expression (P=0.004) and reduced ROR-γt mRNA levels compared to the OT group .

Enhanced Regulatory T Cell Development:
The combination therapy significantly increased Foxp3 and IL-10 mRNA expression, enhanced Foxp3 protein levels, and promoted the induction of CD4+CD25+Foxp3+ regulatory T cells compared to oral tolerance alone . This suggests a potent enhancement of the tolerogenic mechanisms.

Comparative Efficacy Table:

These findings suggest that anti-IL-9 antibody enhances oral tolerance mechanisms, making the combination a potentially effective approach for allergen immunotherapy in patients with uncontrolled allergic airway diseases .

What are the optimal protocols for using IL-9 antibodies in flow cytometry experiments?

Flow cytometry is a powerful technique for detecting IL-9 and studying IL-9-producing cells. Here is a detailed protocol for using IL-9 antibodies in flow cytometry experiments:

Cell Preparation and Stimulation Protocol:

• Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation.

• Culture 1-5 × 10^6 cells/mL in complete medium (RPMI 1640 with 10% FBS, 2mM L-glutamine, and antibiotics).

• Stimulate cells with:

  • Plate-bound anti-CD3 monoclonal antibody (5 μg/mL)

  • Anti-CD28 monoclonal antibody (2 μg/mL)

  • Recombinant Human IL-4 (10 ng/mL)

  • Anti-Human IFN-gamma monoclonal antibody (20 μg/mL)

• Incubate for 5 days at 37°C in 5% CO2 .

Intracellular Staining Protocol:

• Harvest cells and wash twice with PBS containing 1% BSA.

• Fix cells using Flow Cytometry Fixation Buffer for 30 minutes at room temperature.

• Permeabilize cells with Flow Cytometry Permeabilization/Wash Buffer I.

• Stain with 5 μL (0.125 μg) per test of Mouse Anti-Human IL-9 APC-conjugated Monoclonal Antibody.

• Include appropriate isotype control (e.g., Mouse IgG2B Isotype Control Antibody).

• Co-stain with other markers as needed (e.g., Mouse Anti-Human IFN-gamma PE-conjugated Monoclonal Antibody).

• Incubate for 30 minutes at 4°C in the dark.

• Wash twice with Permeabilization/Wash Buffer.

• Resuspend in appropriate buffer for analysis .

Optimization Tips:

• Ensure adequate cell stimulation to induce IL-9 production

• Optimize antibody concentration for your specific cell type

• Include appropriate positive and negative controls

• Consider using protein transport inhibitors (e.g., Brefeldin A or Monensin) during the last 4-6 hours of stimulation to enhance cytokine detection

• Titrate antibodies to determine optimal concentration for specific cell populations

• For detecting low-frequency IL-9-producing cells, collect sufficient events (>100,000)

Troubleshooting Common Issues:

• Low signal: Increase stimulation time or adjust stimulation conditions

• High background: Optimize antibody dilution, check fixation/permeabilization efficiency

• Poor resolution: Ensure proper compensation when using multiple fluorochromes

This protocol has been optimized based on published methods and provides a robust approach for detecting IL-9-producing cells using flow cytometry .

How can researchers effectively design neutralization experiments using anti-IL-9 antibodies?

Designing effective neutralization experiments with anti-IL-9 antibodies requires careful consideration of multiple experimental parameters:

Experimental Design Framework:

• Determine Neutralization Potency:

  • Establish a dose-response curve using recombinant IL-9 to stimulate a responsive cell line (e.g., MO7e human megakaryocytic leukemic cell line)

  • Measure proliferation or another IL-9-dependent response

  • Add increasing concentrations of anti-IL-9 antibody to determine the neutralization dose (ND50)

  • The typical ND50 for commercial anti-IL-9 antibodies is 2-5 μg/mL in the presence of 5 ng/mL recombinant Human IL-9

• In Vitro Neutralization Protocol:

  • Prepare target cells in appropriate medium

  • Pre-incubate anti-IL-9 antibody with recombinant IL-9 for 30-60 minutes at 37°C

  • Add the antibody-cytokine mixture to cells

  • Include appropriate controls:

    • Positive control: IL-9 alone

    • Negative control: media only

    • Isotype control: irrelevant antibody of same isotype

  • Incubate for 24-72 hours depending on the readout

  • Measure response (proliferation, signaling, gene expression)

• In Vivo Neutralization Experimental Design:

  • Determine appropriate dosage based on in vitro potency (typically 50-200 μg per mouse)

  • Establish administration schedule (e.g., during immunotherapy as in the OT+IL9AB model)

  • Choose appropriate routes of administration (intraperitoneal, intravenous, or subcutaneous)

  • Include proper controls:

    • Isotype control antibody

    • Vehicle control

    • Dose-response groups

• Critical Readouts for IL-9 Neutralization:

  • Cellular responses: Changes in T cell subsets (Th2, Th9, Th17, Tregs)

  • Molecular markers: Expression of transcription factors (PU.1, ROR-γt, GATA3, Foxp3)

  • Cytokine profiles: IL-4, IL-10, IL-17

  • Antibody responses: IgE levels

  • Tissue inflammation: Eosinophil infiltration, tissue pathology

Example Protocol for In Vivo IL-9 Neutralization in Allergic Models:

• Sensitize mice with allergen (e.g., ovalbumin) on days 0 and 14

• Administer oral tolerance protocol (feed OVA) on days 28-34

• During immunotherapy (days 28-34), inject anti-IL-9 antibody (100 μg/mouse) every other day

• Challenge with allergen on days 41-45

• Assess outcomes:

  • Measure allergic symptoms

  • Collect serum for OVA-specific IgE measurement

  • Harvest tissues for histology and eosinophil counting

  • Extract RNA for cytokine and transcription factor mRNA analysis

  • Isolate cells for flow cytometry analysis of T cell subsets

This structured approach ensures robust and reproducible neutralization experiments that can effectively evaluate the role of IL-9 in various biological processes.

How should researchers interpret conflicting results in IL-9 antibody research across different disease models?

Interpreting conflicting results in IL-9 antibody research requires a systematic analysis of experimental variations and contextual factors:

Analytical Framework for Resolving Conflicts:

Researchers should therefore interpret IL-9 antibody results within their specific experimental context and avoid generalizing findings across different disease models without careful consideration of these variables.

How can machine learning approaches improve the design and specificity of IL-9 antibodies?

Machine learning approaches offer several promising avenues for enhancing IL-9 antibody design and specificity:

Sequence-Function Relationship Prediction:
Recent research demonstrates that machine learning models can successfully predict antibody targets based on genetic sequences with approximately 85% accuracy . Building on this foundation, researchers can develop specialized models to:

• Predict which specific epitopes on IL-9 an antibody sequence will bind to

• Estimate the binding affinity and neutralization potency of candidate antibodies

• Identify sequences likely to produce cross-reactivity with other cytokines

Epitope Mapping Optimization:
Machine learning can analyze antibody-antigen interaction data to:

• Identify critical binding residues on IL-9 that confer highest specificity

• Map conformational epitopes that may not be evident from linear sequence analysis

• Predict epitope accessibility in native IL-9 versus its receptor-bound state

Antibody Engineering Applications:
As Professor Nicholas Wu notes, "If we can make these predictions based on antibody sequence, we might also be able to go back and design antibodies that bind to specific pathogens" . For IL-9 research, this approach could:

• Guide modifications to enhance antibody specificity for particular IL-9 domains

• Design antibodies that specifically block IL-9 interaction with its receptor

• Create antibodies targeting functionally distinct regions of IL-9

Implementation Strategy:
To harness machine learning for IL-9 antibody design, researchers should:

• Compile comprehensive datasets of IL-9 antibody sequences with known functional characteristics

• Train models on multiple parameters (sequence, structure, binding affinity, neutralization capacity)

• Validate predictions through experimental testing

• Implement iterative learning approaches where experimental results refine the model

Anticipated Advances:
Within the next 5 years, machine learning approaches could enable:

• Rational design of IL-9 antibodies with enhanced specificity and reduced off-target effects

• Development of antibodies targeting specific conformational states of IL-9

• Creation of antibodies that selectively block IL-9 interaction with specific cell types

• Optimization of antibody properties for particular research or therapeutic applications

This integration of computational and experimental approaches represents a paradigm shift in antibody design, potentially reducing development time while increasing specificity and efficacy of anti-IL-9 antibodies for both research and clinical applications.

What are the challenges in translating IL-9 antibody research findings from animal models to human applications?

Translating IL-9 antibody research findings from animal models to human applications faces several significant challenges:

Species-Specific Differences in IL-9 Biology:
Human and mouse IL-9 share approximately 67% amino acid sequence homology, creating potential differences in:

• Receptor binding dynamics and signaling pathways

• Cell type-specific expression patterns

• Functional roles in immune responses

• Regulation of IL-9 production

For example, while anti-IL-9 antibody treatment in mouse models shows significant reduction in allergic inflammation , human studies with anti-IL-9 monoclonal antibodies have shown mixed results, with "promising clinical activities" in mild to moderate asthma but "no improvement in symptoms in adults with uncontrolled asthma" .

Immunological Context Variations:
The complex immunological environment differs between species:

• Mouse models typically use inbred strains with homogeneous genetic backgrounds

• Human populations have diverse genetic factors affecting IL-9 responses

• Pre-existing immune status and environmental exposures modify IL-9 functions

• Human allergic conditions develop over years, unlike accelerated experimental models

Technical and Methodological Barriers:
Transitioning from animal research to human applications involves:

• Humanizing mouse antibodies or developing fully human antibodies

• Adjusting dosing regimens for human pharmacokinetics

• Developing appropriate biomarkers to track efficacy

• Designing clinical trials that capture relevant outcomes

Specific Translation Challenges Table:

Evidence of Translation Challenges:
The study noting that anti-IL-9 monoclonal antibody showed "acceptable safety profiles and promising clinical activities" in adults with mild to moderate asthma, but "no improvement in symptoms in adults with uncontrolled asthma" , highlights the challenge of translating preclinical successes to clinical outcomes.

Strategic Approaches for Improving Translation:

• Develop humanized mouse models expressing human IL-9 and IL-9R

• Conduct parallel studies in multiple species (mouse, non-human primate, human)

• Focus on robust, mechanistically-defined endpoints rather than global disease measures

• Identify patient subpopulations most likely to benefit from IL-9 targeting

• Consider combination approaches targeting multiple pathways simultaneously

Understanding and addressing these challenges is essential for the successful translation of promising IL-9 antibody research findings into effective human therapeutic applications.

How might IL-9 antibodies be integrated with other immunotherapeutic approaches for enhanced efficacy?

IL-9 antibodies show considerable potential for integration with other immunotherapeutic approaches to create synergistic treatment strategies:

Combination with Allergen-Specific Immunotherapy (AIT):
The most direct evidence for combination therapy comes from studies showing that anti-IL-9 antibody increases the effect of allergen-specific oral tolerance . This synergistic approach could be extended to clinical allergen immunotherapy by:

• Administering anti-IL-9 antibodies during the build-up phase of AIT

• Using IL-9 blockade to decrease adverse reactions to immunotherapy

• Combining IL-9 neutralization with modified allergen preparations

• Creating time-release formulations that coordinate IL-9 blockade with allergen exposure

Integration with Other Cytokine-Targeting Biologics:
IL-9 functions within a complex cytokine network, suggesting potential benefits from combination approaches:

Cell-Based Therapy Integration:
IL-9 antibodies could enhance the efficacy of cellular immunotherapies:

• Use in combination with regulatory T cell therapy to enhance tolerance induction

• Integration with CAR-T approaches for cancer to modulate the tumor microenvironment

• Pretreatment before adoptive cell transfer to create a favorable cytokine environment

Novel Delivery Platforms:
Advanced delivery systems could optimize IL-9 antibody integration:

• Bispecific antibodies targeting both IL-9 and another inflammatory mediator

• Nanoparticle encapsulation for targeted delivery to specific tissues

• Inhaled formulations for respiratory conditions to maximize local effects

• Controlled-release implants for sustained IL-9 neutralization during immunotherapy

Personalized Approach for Targeted Patient Populations:
Integration strategies should be tailored based on patient characteristics:

• Genetic testing for IL-9/IL-9R polymorphisms to identify likely responders

• Biomarker profiling to determine optimal combination therapies

• Disease phenotyping to match specific combination approaches to patient subgroups

• Monitoring of IL-9 levels to guide titration of combination therapies

Experimental Evidence Supporting Integration:
Research has demonstrated that anti-IL-9 antibody enhances oral tolerance by decreasing allergic symptoms, OVA-specific IgE levels, and tissue eosinophilia while promoting regulatory T cell development . This provides a mechanistic foundation for integration with other tolerance-inducing approaches.